164 results on '"Jacobus P.J. Ungerer"'
Search Results
152. A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial
- Author
-
Dwarakanathan Ranganathan, Matthew J. Roberts, Brett McWhinney, George John, Jeffrey Lipman, Jason A. Roberts, Megan Purvey, Reza Reyaldeen, Jacobus P.J. Ungerer, Helen Healy, Paul Kubler, Aaron Lim, and Robert G. Fassett
- Subjects
medicine.medical_specialty ,Lupus nephritis ,Mycophenolic acid ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Protocol ,medicine ,Pharmacokinetics ,Dosing ,Renal Medicine ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,Lupus Nephritis ,Mycophenolate Sodium ,Clinical trial ,Transplantation ,Therapeutic drug monitoring ,Inclusion and exclusion criteria ,business ,medicine.drug - Abstract
Introduction Mycophenolate sodium, an enteric-coated tablet (EC-MPS), is as effective and safe as mycophenolate mofetil (MMF) in preventing transplant rejection. EC-MPS and MMF improve the outcome of severe lupus nephritis (LN) and have fewer side effects than pulsed intravenous cyclophosphamide. Blood concentrations of mycophenolic acid (MPA), the active metabolite of EC-MPS, vary between participants despite fixed dosing. Interpatient variability has been studied in transplantation, but not well documented in LN. The relationship between MPA concentration and its clinical effect on LN has not been described. Methods and analysis This is a prospective, open-label, randomised controlled trial. –32 participants with LN who meet the inclusion and exclusion criteria will be randomised into two groups: one receiving a fixed dose of EC-MPS and the second, a dosing regimen that is titrated with therapeutic drug monitoring. Included participants will have blood sampled over a period of 8–12 h on three different occasions. Pharmacokinetic parameters will be calculated using non-compartmental methods. Ethics and dissemination The Human Research and Ethics Committee of the Royal Brisbane Women9s Hospital have approved this study. The study is registered with Australian and New Zealand Clinical Trials Registry—ACTRN12611000798965 We planned to present the de-identified information at conferences and publish the results in medical journals. Trial Registration ACTRN12611000798965
- Published
- 2013
153. Validation of high-sensitivity troponin I in a 2-h diagnostic strategy to assess 30-day outcomes in emergency-department patients with possible acute coronary syndrome
- Author
-
Richard W. Troughton, Peter M. George, Tobias Reichlin, Allan S. Jaffe, Chris J. Pemberton, Christian Mueller, Raphael Twerenbold, Miriam Reiter, Christopher J. Hammett, Jacobus P.J. Ungerer, B. Meller, Philip Haaf, Martin Than, Sally Aldous, William F. Peacock, Arvin Lamanna, Louise Cullen, Kevin Chu, Mira Mueller, Christa Zellweger, Karin Wildi, Christopher M. Reid, Tamina Mosimann, Anthony F T Brown, Jillian R Tate, Karsten Murray, Christopher M. Florkowski, Dylan Flaws, Maria Rubini Gimenez, Jaimi H. Greenslade, William A. Parsonage, Joanne M. Deely, and A. Mark Richards
- Subjects
Chest Pain ,medicine.medical_specialty ,Acute coronary syndrome ,acute myocardial infarction ,030204 cardiovascular system & hematology ,APACE ,Chest pain ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Myocardial infarction ,cardiovascular diseases ,Acute Coronary Syndrome ,Prospective cohort study ,TIMI ,business.industry ,high-sensitivity troponin I ,Coronary Care Units ,Troponin I ,Reproducibility of Results ,Prognosis ,medicine.disease ,3. Good health ,Early Diagnosis ,Practice Guidelines as Topic ,Cohort ,Cardiology ,chest pain ,ADAPT ,medicine.symptom ,business ,Cardiology and Cardiovascular Medicine ,Mace ,Follow-Up Studies ,Cohort study - Abstract
Objectives The study objective was to validate a new high-sensitivity troponin I (hs-TnI) assay in a clinical protocol for assessing patients who present to the emergency department with chest pain. Background Protocols using sensitive troponin assays can accelerate the rule out of acute myocardial infarction in patients with low-risk (suspected) acute coronary syndrome (ACS). Methods This study evaluated 2 prospective cohorts of patients in the emergency department with ACS in an accelerated diagnostic pathway integrating 0- and 2-h hs-TnI results, Thrombolysis In Myocardial Infarction (TIMI) risk scores, and electrocardiography. Strategies to identify low-risk patients incorporated TIMI risk scores = 0 or ≤1. The primary endpoint was a major adverse cardiac event (MACE) within 30 days. Results In the primary cohort, 1,635 patients were recruited and had 30-day follow-up. A total of 247 patients (15.1%) had a MACE. The finding of no ischemic electrocardiogram and hs-TnI ≤26.2 ng/l with the TIMI = 0 and TIMI ≤1 pathways, respectively, classified 19.6% (n = 320) and 41.5% (n = 678) of these patients as low risk; 0% (n = 0) and 0.8% (n = 2) had a MACE, respectively. In the secondary cohort, 909 patients were recruited. A total of 156 patients (17.2%) had a MACE. The TIMI = 0 and TIMI ≤1 pathways classified 25.3% (n = 230) and 38.6% (n = 351), respectively, of these patients as low risk; 0% (n = 0) and 0.8% (n = 1) had a MACE, respectively. Sensitivity, specificity, and negative predictive value for TIMI = 0 in the primary cohort were 100% (95% confidence interval [CI]: 98.5% to 100%), 23.1% (95% CI: 20.9% to 25.3%), and 100% (95% CI: 98.8% to 100%), respectively. Sensitivity, specificity, and negative predictive value for TIMI ≤1 in the primary cohort were 99.2 (95% CI: 97.1 to 99.8), 48.7 (95% CI: 46.1 to 51.3), and 99.7 (95% CI: 98.9 to 99.9), respectively. Sensitivity, specificity, and negative value for TIMI ≤1 in the secondary cohort were 99.4% (95% CI: 96.5 to 100), 46.5% (95% CI: 42.9 to 50.1), and 99.7% (95% CI: 98.4 to 100), respectively. Conclusions An early-discharge strategy using an hs-TnI assay and TIMI score ≤1 had similar safety as previously reported, with the potential to decrease the observation periods and admissions for approximately 40% of patients with suspected ACS. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study, NCT00470587 ; A 2hr Accelerated Diagnostic Protocol to Assess patients with chest Pain symptoms using contemporary Troponins as the only biomarker [ADAPT]: a prospective observational validation study, ACTRN12611001069943 )
- Published
- 2013
- Full Text
- View/download PDF
154. The hitchhiker’s guide to the troponin universe
- Author
-
Jacobus P.J. Ungerer
- Subjects
medicine.medical_specialty ,Cardiac troponin ,biology ,business.industry ,Research findings ,medicine.disease ,Troponin ,Pathology and Forensic Medicine ,Highly sensitive ,Internal medicine ,medicine ,Cardiology ,biology.protein ,Myocardial infarction ,business - Abstract
Pathology Queensland consists of a network of 34 laboratories spread throughout Queensland. In 2007, biochemistry testing was standardised state-wide with the introduction of Beckman Coulter analysers. Their accuTnI assay was used for measuring cardiac troponin I. Simultaneously, the Universal Definition of Myocardial Infarction, as defined in 2000, was introduced with a new cardiac troponin I cut-off level according to the 99 th percentile. A number of issues ensued. The diagnosis of myocardial infarction increased dramatically straining emergency and cardiology resources. Unexpectedly, randomly occurring false positive results (flyers) were identified that had a significant impact on clinical intervention. ‘Highly sensitive' cardiac troponin assays were introduced into the market adding to the conundrum. We report more than 300 000 cardiac troponin I tests annually. Our experience with cardiac troponin testing will be presented as well as our research findings into the performance of troponin assays. Unlike our fictional Hitchhiker's Guide we have pursued analytical performance relentlessly. We have characterised assay robustness and between-assay variance, and presented guidance on how to universally define significant changes in serial cardiac troponin results. I will entertain our perspective regarding the value of ‘highly sensitive' cardiac troponin.
- Published
- 2013
155. Diagnosis of AMI Using Sex-Specific Cut-Off Values of a Highly Sensitive Troponin I Assay in Emergency Department Patients With Chest Pain
- Author
-
Jaimi H. Greenslade, Mark Richards, C. Hammett, Peter M. George, Sally Aldous, William A. Parsonage, Louise Cullen, Chris J. Pemberton, Jacobus P.J. Ungerer, Martin Than, and Arvin Lamanna
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,Troponin I ,Emergency medicine ,Medicine ,Emergency department ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Chest pain ,Sex specific ,Highly sensitive - Published
- 2013
156. Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial
- Author
-
Anne B. Chang, Andrew Wilson, Joanne Tuppin, Paul J. Torzillo, Kerry-Ann F. O'Grady, Ian Brent Masters, Theo P. Sloots, Gabrielle B. McCallum, Ian M. Mackay, Peter S. Morris, Jacobus P.J. Ungerer, Colin F. Robertson, Peter Van Asperen, Keith Grimwood, Catherine A. Byrnes, and Helen M. Buntain
- Subjects
Spirometry ,medicine.medical_specialty ,Exacerbation ,Placebo-controlled study ,Medicine (miscellaneous) ,Azithromycin ,Amoxicillin-Potassium Clavulanate Combination ,Cystic fibrosis ,law.invention ,Study Protocol ,03 medical and health sciences ,0302 clinical medicine ,Clinical Protocols ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,Outcome Assessment, Health Care ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Intensive care medicine ,Placebo ,lcsh:R5-920 ,Amoxycillin-clavulanate ,Bronchiectasis ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Anti-Bacterial Agents ,3. Good health ,Chronic cough ,Pulmonary exacerbations ,030228 respiratory system ,Sample Size ,medicine.symptom ,lcsh:Medicine (General) ,business ,medicine.drug - Abstract
Background Bronchiectasis unrelated to cystic fibrosis (CF) is being increasingly recognized in children and adults globally, both in resource-poor and in affluent countries. However, high-quality evidence to inform management is scarce. Oral amoxycillin-clavulanate is often the first antibiotic chosen for non-severe respiratory exacerbations, because of the antibiotic-susceptibility patterns detected in the respiratory pathogens commonly associated with bronchiectasis. Azithromycin has a prolonged half-life, and with its unique anti-bacterial, immunomodulatory, and anti-inflammatory properties, presents an attractive alternative. Our proposed study will test the hypothesis that oral azithromycin is non-inferior (within a 20% margin) to amoxycillin-clavulanate at achieving resolution of non-severe respiratory exacerbations by day 21 of treatment in children with non-CF bronchiectasis. Methods This will be a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial involving six Australian and New Zealand centers. In total, 170 eligible children will be stratified by site and bronchiectasis etiology, and randomized (allocation concealed) to receive: 1) azithromycin (5 mg/kg daily) with placebo amoxycillin-clavulanate or 2) amoxycillin-clavulanate (22.5 mg/kg twice daily) with placebo azithromycin for 21 days as treatment for non-severe respiratory exacerbations. Clinical data and a parent-proxy cough-specific quality of life (PC-QOL) score will be obtained at baseline, at the start and resolution of exacerbations, and on day 21. In most children, blood and deep-nasal swabs will also be collected at the same time points. The primary outcome is the proportion of children whose exacerbations have resolved at day 21. The main secondary outcome is the PC-QOL score. Other outcomes are: time to next exacerbation; requirement for hospitalization; duration of exacerbation, and spirometry data. Descriptive viral and bacteriological data from nasal samples and blood inflammatory markers will be reported where available. Discussion Currently, there are no published randomized controlled trials (RCT) to underpin effective, evidence-based management of acute respiratory exacerbations in children with non-CF bronchiectasis. To help address this information gap, we are conducting two RCTs. The first (bronchiectasis exacerbation study; BEST-1) evaluates the efficacy of azithromycin and amoxycillin-clavulanate compared with placebo, and the second RCT (BEST-2), described here, is designed to determine if azithromycin is non-inferior to amoxycillin-clavulanate in achieving symptom resolution by day 21 of treatment in children with acute respiratory exacerbations. Trial registration Australia and New Zealand Clinical Trials Register (ANZCTR) number http://ACTRN12612000010897. http://www.anzctr.org.au/trial_view.aspx?id=347879
- Published
- 2013
157. A Study of the Effect of the Manufacturers Advised Recalculation of the High Sensitivity Troponin T Assay on the Early Detection of Acute Myocardial Infarction in Patients Presenting to the Emergency Department
- Author
-
Carel J. Pretorius, Jillian R Tate, Jacobus P.J. Ungerer, Louise Cullen, William A. Parsonage, Arvin Lamanna, Jaimi H. Greenslade, C. Hammett, Kevin Chu, and Anthony F T Brown
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,Early detection ,Emergency department ,medicine.disease ,Internal medicine ,Cardiology ,Medicine ,In patient ,Myocardial infarction ,High Sensitivity Troponin T Assay ,Cardiology and Cardiovascular Medicine ,business - Abstract
index admission. 313 (19.7%) patients had an elevated hscTnI value at 0 or 2 h and 494 (31.1%) patients had an elevated hs-cTnT value. Sensitivity for AMI was equivalent between hs-cTnI and hs-cTnT (96.2% versus 94.8%, p= 0.61). Specificity for AMI was higher using hs-cTnI at zero (93.6% versus 80.5%, p< 0.01) and two hours (92.8% vs. 80.8%, p< 0.01). Conclusions: The hs-cTnI and hs-cTnT assays were equally sensitive forearlydiagnosisofAMIbut thehs-cTnI assay was significantly more specific. http://dx.doi.org/10.1016/j.hlc.2013.05.494
- Published
- 2013
158. NR1I2 Polymorphisms Are Related to Tacrolimus and Prednisolone Dose-Adjusted Exposure and BK Viraemia in Adult Kidney Transplantation
- Author
-
Katherine A. Barraclough, David W. Johnson, Christine E. Staatz, Rebecca Rockett, D. R. Leary, Troels K Bergmann, Brett McWhinney, Seweryn Bialasiewicz, N. M. Isbel, Jacobus P.J. Ungerer, Scott B. Campbell, and Katie J. Lee
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Prednisolone ,medicine.disease ,business ,Gastroenterology ,Kidney transplantation ,Tacrolimus ,medicine.drug - Published
- 2012
159. Significance of adenosine deaminase activity and its isoenzymes in tuberculous effusions
- Author
-
Jacobus P.J. Ungerer, Johannes H. Retief, Heila M. Oosthuizen, and S. H. Bissbort
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,Tuberculosis ,Adenosine Deaminase ,Critical Care and Intensive Care Medicine ,Isozyme ,Pleural disease ,Adenosine deaminase ,medicine ,Humans ,Tuberculosis, Pulmonary ,Aged ,Aged, 80 and over ,Lung ,biology ,business.industry ,Respiratory disease ,Ascites ,Middle Aged ,medicine.disease ,Isoenzymes ,Pleural Effusion ,medicine.anatomical_structure ,Effusion ,Spectrophotometry ,Immunology ,biology.protein ,Electrophoresis, Polyacrylamide Gel ,Female ,Cardiology and Cardiovascular Medicine ,Complication ,business ,Biomarkers - Abstract
Adenosine deaminase (ADA) activity is increased in effusions caused by certain clinical conditions including tuberculosis and bacterial infections. In this study, the ADA isoenzyme patterns in tuberculous and parainfective effusions were investigated to determine the isoenzyme responsible for this increase in activity. Fifty-one tuberculous effusions and six parainfective effusions were investigated. All effusions had increased ADA activity (median values of 126 and 127 units/L, respectively). In the tuberculous effusions, ADA2 isoenzyme was found to be primarily responsible for total activity, with a median contribution of 88 percent. The ADA1 (both ADA1m and ADA1c isoenzymes) was the major isoenzyme in the parainfective effusions with a median contribution of 70 percent. The ADA2 isoenzyme activity most likely reflects monocyte-macrophage turnover or activity, while ADA1 probably originates from lymphocytes or neutrophils. It is therefore essential to determine the isoenzyme profile when interpreting ADA activity levels in effusions. The measurement of the individual isoenzymes will enhance the diagnostic utility of ADA activity determinations in pleural effusions.
- Published
- 1994
160. Elevated adenosine deaminase activity in patients with HIV and tuberculous peritonitis
- Author
-
Jacobus P.J. Ungerer, Mahomed A. Sathar, Ahmed E. Simjee, Eleanor Gouws, and Fathima Lockhat
- Subjects
Adult ,Liver Cirrhosis ,Male ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Cirrhosis ,Tuberculosis ,Adenosine Deaminase ,Peritonitis, Tuberculous ,Peritonitis ,Malignancy ,Sensitivity and Specificity ,Gastroenterology ,Mycobacterium tuberculosis ,Interferon-gamma ,immune system diseases ,HIV Seronegativity ,Internal medicine ,Immunopathology ,HIV Seropositivity ,medicine ,Humans ,Prospective Studies ,Sida ,Peritoneal Neoplasms ,Aged ,AIDS-Related Opportunistic Infections ,Hepatology ,biology ,business.industry ,Liver Neoplasms ,Ascites ,nutritional and metabolic diseases ,hemic and immune systems ,Middle Aged ,medicine.disease ,biology.organism_classification ,Isoenzymes ,enzymes and coenzymes (carbohydrates) ,Immunology ,Female ,Complication ,business - Abstract
OBJECTIVE To evaluate the diagnostic potential of the ADA(T), ADA isoenzymes (ADA1 and ADA2) and the interferon-gamma (IFN-gamma) test in HIV-seropositive patients with tuberculous peritonitis. METHODS Ascitic ADA(T), ADA1, ADA2 and IFN-gamma were prospectively evaluated in HIV-seronegative patients with tuberculous peritonitis (n = 17), HIV-seropositive patients with tuberculous peritonitis (n = 6) and in patients with cirrhosis (n = 22) and malignancy (n = 5). RESULTS ADA(T) and ADA2 isoenzyme activities of HIV-seronegative (ADA(T) = 109 U/l; ADA2 = 94 U/l) and HIV-seropositive (ADA(T) = 109.5 U/l; ADA2 = 95.5 U/l) patients with tuberculous peritonitis, respectively, were significantly different (P < 0.001) from patients with cirrhosis (ADA(T) = 10.5 U/l; ADA2 = 8 U/l) and malignancy (ADA(T) = 13 U/l; ADA2 = 11 U/l). There was no significant difference in ADA(T) and ADA2 activities between HIV-seropositive and seronegative patients with tuberculous peritonitis. There was no significant correlation between ADA, its isoenzymes and IFN-gamma. CONCLUSIONS The diagnosis of tuberculous peritonitis can be made by a sensitive, relatively non-invasive procedure in both HIV-seronegative and seropositive patients with minimal risk to the patient and the investigator. The diagnostic value of ADA(T) is not enhanced by measuring ADA isoenzymes or IFN-gamma.
- Published
- 1999
161. Adenosine deaminase in pleural effusions
- Author
-
Jacobus P.J. Ungerer and S. H. Bissbort
- Subjects
Text mining ,Adenosine deaminase ,biology ,business.industry ,Biochemistry (medical) ,Clinical Biochemistry ,Cancer research ,biology.protein ,Medicine ,business - Published
- 1996
162. Serum Lactate Dehydrogenase Activity in Exfoliative Dermatitis
- Author
-
Jacobus P.J. Ungerer and Witold Kamil Jacyk
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Medicine ,Dermatology ,General Medicine ,Exfoliative dermatitis ,business ,Serum lactate dehydrogenase - Published
- 1991
163. Molecular forms of adenosine deaminase in pleural effusions
- Author
-
S. M. Grobler and Jacobus P.J. Ungerer
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,Cellular immunity ,Tuberculosis ,Lymphoma ,Adenosine Deaminase ,Nucleoside Deaminases ,Biochemistry ,Adenosine deaminase ,immune system diseases ,medicine ,Humans ,Empyema ,Polyacrylamide gel electrophoresis ,Tuberculosis, Pulmonary ,biology ,Chemistry ,nutritional and metabolic diseases ,hemic and immune systems ,medicine.disease ,Molecular biology ,Pleural Effusion ,enzymes and coenzymes (carbohydrates) ,Leukemia ,Leukemia, Myeloid ,biology.protein ,Electrophoresis, Polyacrylamide Gel ,Chronic myelogenous leukemia - Abstract
The molecular forms of adenosine deaminase (ADA) were studied in pleural effusions with high ADA activity. The molecular forms were separated by polyacrylamide gel electrophoresis (PAGE), and the molecular masses estimated by gel filtration. Effusions investigated were: tuberculosis (TB) (20 cases), lymphoma (3 cases), chronic myelogenous leukemia (1 case) and empyema (6 cases). Two ADA forms were identified, a small form (Smf-ADA) and a large form (Lmf-ADA). Without exception, the tuberculous effusions have shown only Lmf-ADA. All the other effusions contained both forms, the Smf-ADA being predominant. This was also the ADA pattern seen in normal lymphocytes. These findings may indicate different mechanisms of ADA release or origins of ADA in the various effusions. The Lmf-ADA may be secreted by activated T cells in TB, which would confirm the notion that ADA activity reflects cellular immunity. In contrast, in the nontuberculous cases the ADA probably leaked from damaged lymphocytes or neutrophils, hence the reflection of the cellular ADA pattern. The PAGE pattern may also be of value in distinguishing between TB and these other causes of high pleural fluid ADA.
- Published
- 1988
164. COMPARISON OF HIGHLY SENSITIVE TROPONIN I AND T RESULTS IN THE DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION
- Author
-
Christopher J. Hammett, Louise Cullen, Carel J. Pretorius, Anthony F T Brown, Kevin Chu, Jill Tate, Jacobus P.J. Ungerer, Jaimi H. Greenslade, and William A. Parsonage
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Early detection ,macromolecular substances ,Emergency department ,Chest pain ,medicine.disease ,Troponin ,Highly sensitive ,Internal medicine ,Troponin I ,medicine ,Cardiology ,biology.protein ,In patient ,cardiovascular diseases ,Myocardial infarction ,medicine.symptom ,business ,Cardiology and Cardiovascular Medicine - Abstract
The performance of highly sensitive troponin assays in the early detection of acute myocardial infarction (AMI) in patients presenting to the emergency department (ED) with chest pain is assay-dependent. The aim was to compare the diagnostic accuracy for AMI of highly sensitive troponin I (hsTnl)
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.